Summary
Dry cough is now recognized as a common side effect of ACE inhibitor therapy. When cough becomes bothersome, no alternative is better than substituting a different class of antihypertensive agents for the offending ACE inhibitors. Losartan potassium represents a new class of antihypertensive agents with a different mechanism of action: it directly blocks the effects of angiotensin (Ang) II at the receptor level, without affecting kininase II-related factors, such as the bradykinin system. As shown in the Losartan Cough Study, the incidence of cough related to a treatment with an AT1 type Ang II receptor antagonist, such as losartan, is significantly lower than that observed with lisinopril and is similar to that of HCTZ in patients with a rechallenged ACE-inhibitor cough. Ang II receptor antagonists represent a potential new treatment for hypertensive patients, which may be especially useful in patients in whom a pharmacological inhibition of RAAS is indicated, but who develop cough with ACE inhibitors.
Keywords
- Antihypertensive Agent
- Losartan Potassium
- Angiotensin Converting Enzyme Gene
- Angiotensin Converting Enzyme Inhibitor Therapy
- RAAS Inhibition
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brunner HR, Nussberger J, Waeber B. 1985. Effects of angiotensin converting enzyme inhibitor: a clinical point of view. J Cardiovasc Pharmacol 7(Suppl 4):73–81.
The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302.
The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435.
Dzau VJ, Creager MA. 1987. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. Cardiol Clin 7: 119–130.
Rush JE, Merrill DD. 1987. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 9(Suppl 3):S99–S107.
Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncio F. 1984. Enalapril worldwild experience. Am J Med 77(Suppl 2A):23–35.
Frolich ED, Cooper RA, Lewis EJ. 1984. Review of the overall experience of captopril in hypertension. Arch Intern Med 144:1441–1444.
McFate Smith W, Kulaga SF, Moncloa F, Pingeon R, Walker JF. 1984. Overall tolerance and safety of enalapril. J Hypertens 2(Suppl 5):S113–S117.
Veterans Administration Cooperative Study group on Antihypertensive Agents. 1984. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 144:1947–1953.
Edwards CR, Padfield PL. 1985. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet 1:30–34.
Jenkins AC, Drelinski GR, Tadros SS, Groel JT, Fand R, Herczog SA. 1985. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 7(Suppl l):S96–S101.
DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors 1986. Med Toxicol 1:122–141.
Irvin JD, Viau JM. 1986. Safety profiles of the angiotensin convering enzyme inhibitors captopril and enalapril. Am J Med 81(Suppl 4C):46–50.
Todd PA, Heel RC. 1986. Enalapril. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198–248.
Weber MA, Zusman RM. 1986. Converting enzyme inhibitors in the treatment of essential hypertension. Drug Ther 16:43–54.
Bolzano K, Arriaga J, Bernai R, Bernades H, Calderon JL, Debruyn J, Dienstl F, Drayer J, Goodfriend TL, Gross W. 1987. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 9(Suppl 3):S43–S47.
Armayor GM, Lopez LM. 1988. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug Intell Clin Pharm 22:365–372.
Brogden RN, Todd PA, Sorkin EM. 1988. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36:54–60.
Graves H. 1986. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther 9:24–38.
Inman WH, Rawson NS, Wilton LV, Pearce GL, Speirs CJ. 1988. Post-marketing surveillance of enalapril. I. Results of prescription-event monitoring. BMJ 297:826–829.
Kostis JB. 1988. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J 116:1591–1605.
Rumboldt Z, Marinkovic M, Drinovec J. 1988. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension. Int J Clin Pharmacol Res 8:181–188.
Warner NJ, Rush JE. 1988. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 35(Suppl 5):89–97.
Weber MA. 1988. Safety issues during antihypertensive treatment with converting enzyme inhibitors. Am J Med 84(Suppl 4A): 16–23.
Arr SM, Woollard ML, Fairhurst G, Pippen CA, Rao SK, Cooper WD. 1985. Safety and efficacy of enalapril in essential hypertension in the elderly. Br J Clin Pharmacol 20:279P–280P.
Jenkins AC, Knill JR, Dreslinki GR. 1985. Captopril in the treatment of elderly hypertensive patient. Arch Intern Med 145:2029–2031.
Creisson C, Baulac L, Lenfant B. 1986. Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study. Postgrad Med J 62(Suppl 1):139–141.
Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP, Nelson EB and the Losartan Cough Study Group. 1994. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 12:1387–1393.
Lacourcière Y, Lefebvre J. 1995. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 11(Suppl F):33F–39F.
Sesoko S, Kaneko Y. 1985. Cough associated with the use of captopril (letter). Arch Intern Med 145:1524.
Israili ZH, Hall WD. 1992. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and physiopathology. Ann Intern Med 117(3):234–242.
Just PM. 1989. The positive association of cough with angiotensin-converting enzyme inhibitors. Ann Pharmacoth 9:82–87.
Inman WH. 1986. Enalapril-induced cough (letter). Lancet 2:1218.
Webb DJ, Benjamin N, Collier JG, Robinson BF. 1986. Enalapril-induced cough (letter). Lancet 2:1094.
Coulter DM, Edwards IR. 1987. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 294:1521–1523.
Goldzer RC, Lilly LS, Solomon HS. 1988. Prevalence of cough during angiotensin-converting enzyme inhibitor therapy (letter). Am J Med 85:887.
Gibson GR. 1989. Enalapril induced cough. Arch Intern Med 149:2701–2703.
Strocchi E, Valtancoli G, Ambrosioni E. 1989. The incidence of cough during treatment with angiotensin converting enzyme inhibitors. J Hypertens 7(Suppl 6):S308–S309.
Poole MD, Postma DS. 1991. Characterization of cough associated with angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg 105:714–716.
Capella D, Torres F, Avila P, Moreno V, Laporte JR. 1991. Cough caused by angiotensin-converting enzyme inhibitors. A series of cases collected by spontaneous notification of adverse reactions. Med Clin (Barc) 96:126–128.
McNally EM. 1987. Cough due to captopril. West J Med 146:226–228.
Faison EP, Nelson EB, Irvin JD. 1991. Profile of angiotensin converting enzyme inhibitor (ACE I) associated cough: Incidence and clinical characteristics. Amer J Hypertens 4(5;Pt2):28A.
Witchitz S, Beaufils M, Liote H, Petroff C. 1989. Complications respiratoires des inhibiteurs de l’enzyme de conversion. (Respiratory complications of converting-enzyme inhibitors) (letter). Presse Med 18(17):896.
Lernhardt EB, Ziegler MG. 1988. Cough caused by cilazapril. Am J Med Sci 296(2):119–120.
Ollivier JP, Ducrocq MB, Droniou J. 1988. Un Effet secondaire des inhibiteurs de l’enzyme de conversion: La Toux. (A side-effect of angiotensin-converting enzyme inhibitors: Cough). Presse Med 16:759–761.
De Groote P, Millaire A, Aisenfarb JC, Marquand A, Ducloux G. 1988. Toux et inhibiteurs de l’enzyme de conversion de l’angiotensine. (Cough and angiotensin-converting enzyme inhibitors). Ann Cardiol Angeiol 37(5):251–253.
Dreslinski GR. 1987. Incidence of cough associatd with captopril therapy (letter). West J Med 146:622.
Strump KO, Lolloch R, Overlack A. 1984. Captopril and enalapril: Evaluation of therapeutic efficacy and safety. Pract Cardiol 10:111–124.
Fuller RW, Choudry NB. 1987. Increased cough reflex associated with angiotensin-converting enzyme inhibitor cough. Br Med J 295:1025–1026.
Lefebvre J, Poirier L, Lacourcière Y. 1992. Prospective trial on captopril-related cough. Ann Pharmacol 26:161–164.
Yeo WW, Ramsay LE. 1990. Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens 4:517–520.
Faison EP, Nelson EB, Irvin JD. 1991. Profile of angiotensin converting enzyme inhibitor (ACE I) associated with cough: incidence and clinical characteristics (abstract 29). Am J Hypertens 4(Suppl):28A.
Chalmers D, Dombey SL, Lawson DH. 1987. Post-marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 24(3):343–349.
Town GI, Hallwright GP, Maling TJB, O’Donnell TV. 1987. Angiotensin-converting enzyme inhibitors and cough. N Z Med J 100:161–163.
Fletcher AE, Palmer AJ, Bulpitt CJ. 1994. Cough with angiotensin converting enzyme inhibitors: How much a problem? J Hypertens 12(Suppl 2):S43–S47.
Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. 1992. Female sex as an important determination of lisinopril-induced cough (letter). Lancet 339:372.
Moore N, Noblet C, Joannides R, Ollagnier M, Imbs JL, Lagier G. 1933. On behaif of the French Pharmacovigilance System: Cough and ACE inhibitors (letter). Lancet 341:61.
Fletcher AE, Bulpitt CJ, Chase D, Collins W, Furberg CD, Goggin TK, Hewett AJ, Neiss AM. 1992. Quality of life on three antihypertensive treatments: cilazapril, atenolol, nifedipine. Hypertension 19:499–507.
Simon SH, Black HR, Moser M, Berland WE. 1992. Cough and ACE inhibitors. Arch Intern Med 152:1698–1700.
Hood S, Nicholls MG, Gilchrist NL. 1987. Cough with angiotensin-converting inhibitors. N Z Med J 100:6–7.
Nicholls GN, Gilchrist NL. 1987. Sulindac and cough induced by converting enzyme inhibitors (letter). Lancet 1:872.
David D and The Fosinopril Cough Study Group. 1994. Multicenter, doubleblind, randomized trial comparing fosinopril to enalapril in patients with previous angiotensin converting enzyme cough, (abstract 512). Presentd at the 24thScientific Meeting of the International Society of Hypertension, Melbourne, Australia.
Skidgel RA, Erdos EG. 1987. Cleavage of peptide bonds by angiotensin I converting enzyme. Agents Actions 22(Suppl):589–596.
Kaufman MP, Coleridge HM, Coleridge JC, Baker DG. 1980. Bradykinin stimulate afferent vagal C-fibers in intrapulmonary airways of dogs. J Appl Physiol 48:511–517.
Varonier HS, Panzani R. 1968. The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Immunol 34:293–296.
Ferner RE, Simpson JM, Rawlins MD. 1987. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) 294:1119–1120.
Greenberg R, Osman GH Jr, O’Keefe EH, Antonaccio MJ. 1979. The effects of captopril (SQ 14,225) on bradykinin-induced bronchoconstriction in the anaesthetised guinea pig. Eur J Pharmacol 57:287–294.
Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. 1992. Effects of nifedipine and indomethacin on cough induced by angiotensin converting enzyme inhibitors: A double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 19:670–673.
Regoli D, Barabe J. 1980. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1–46.
Goetzl EJ. 1984. Asthma: new mediators and old problems (editorial). N Eng J Med 311:252–253.
Dixon CM, Fuller RW, Barnes PJ. 1987. The effects of the angiotensin converting enzyme inhibitor, ramipril, on bronchial response to inhaled histamine and bradykinin in asthamatic subjects. Br J Clin Pharmacol 23:91–93.
Morice AH, Lowry R, Brown MJ, Higenbottam T. 1987. Angiotensin-converting enzyme and the cough reflex. Lancet 2(8568):1116–1118.
Meeker DP, Wiedemann HP. 1990. Drug-induced bronchospasm. Clinics in Chest Medicine 11(1):163–175.
Korpas J, Tomori Z. 1979. Physiology of the cough reflex. Cough and other respiratory reflexes. S. Karger Publisher 15–18.
Kaufman J, Casanova JE, Riendl P, Schlueter DP. 1989. Bronchial hyperactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 95(3):544–548.
Boulet LP, Milot J, Lampron N, Lacourcière Y. 1989. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 261:413–416.
Yeo WW, Ramsay LE, Morice AH. 1991. ACE inhibitor cough: A genetic link? (letter) Lancet 337:187.
Kreft-Jais C, Laforest L, Bonnardeaux A, Jeunemaître X. 1994. No relation between the insertion/ deletion (I/D) polymorphism of the angiotensin I converting enzyme (ACE) gene and ACE-inhibitor cough, (abstract 519). J Hypertens 12(Suppl 3):S93.
O’Kane KPJ, Johnstone HA, Webb DJ. 1994. The risk of ACE inhibitor cough is not associated with ACE genotype, (abstract 524). J Hypertens 12(Suppl 3):S94.
Turgeon J, Roy S, Belley D, Poirier L, Robitaille NM. 1994. Link between ACE inhibitor associated cough and XBA I DNA restriction fragments of mutant alteles of CYP2D6. (abstract 85). J Hypertens 12(Suppl 3):S154.
Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. 1990. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Therap 252:719–725.
Lacourcière Y, Lefebvre J, Nakhle G, Faison EP, Snavely DB, Nelson EB. 1994. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 12(Suppl 2):S49–S53.
Fletcher AE, Bulpitt CJ, Hawkins CM, Havinga TK, Tenberge BS, May JF, Schuurman FH, van der Veur E, We sseling H. 1990. Quality of life on antihypertensive therapy; a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 8:463–466.
Nelson DE, Moyse DM, O’Neil JM, Boger RS, Glassman HN, Kleinen HD. 1993. Renin inhibitor, Abott-72517, does not induce characteristic angiotensin converting enzyme inhibitor cough (Abstract 1934). Circulation 1:36.
Reisin L, Schneeweiss A. 1992. Complete spontaneous remission of cough induced by ACE-inhibitors during chronic therapy in hypertensive patients. J Hum Hypertens 6:333–335.
Stroller JR, Elghazawi A, Metha AL, Vidt DG. 1988. Captopril-induced cough. Chest 93(3):659–661.
Karlberg BE. 1993. Cough and inhibition of the renin-angiotensin system. J Hypertens 11(3):S49–S52.
Lindgren BR, Anderson RG. 1989. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp 4:369–380.
Thysell H, Anderson KE, Andersen SL, Ekman R. 1988. Angiotensin converting-enzyme inhibition, cough and the serum concentration of substance P. Eur J Clin Pharmacol 34:649–650.
Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. 1993. Comparison of angiotensin-converting enzyme inhibition with angiotensin 11 receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22:579–584.
Smith MC, Barrows S, Shahinfar S, Simpson RL, Weigel K, Dunn MJ. 1993. The effect of the nonpeptide All antagonist losartan on systemic blood pressure and renal and extrarenal prostaglandin (PG) production in women with essential hypertension (abstract). J Amer Soc Nephrol 4(3):540.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lacourcière, Y., Lefebvre, J. (1998). Cough Induced by Pharmacological ModulatiOn of the Renin-Angiotensin-Aldosterone System. Angiotensin Converting Enzyme Inhibitors And Angiotensin II Receptor Antagonists. In: Dhalla, N.S., Zahradka, P., Dixon, I.M.C., Beamish, R.E. (eds) Angiotensin II Receptor Blockade Physiological and Clinical Implications. Progress in Experimental Cardiology, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5743-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5743-2_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7631-6
Online ISBN: 978-1-4615-5743-2
eBook Packages: Springer Book Archive